Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity.
about
Pharmacotherapy for pulmonary hypertensionPersistent Challenges in Pediatric Pulmonary Hypertension.Change in Pediatric Functional Classification During Treatment and Morbidity and Mortality in Children with Pulmonary HypertensionFetal production of growth factors and inflammatory mediators predicts pulmonary hypertension in congenital diaphragmatic hernia.B-type natriuretic peptide: prognostic marker in congenital diaphragmatic herniaPersistence of pulmonary hypertension by echocardiography predicts short-term outcomes in congenital diaphragmatic herniaMolecular physiopathogenetic mechanisms and development of new potential therapeutic strategies in persistent pulmonary hypertension of the newbornAltered pulmonary artery endothelial-smooth muscle cell interactions in experimental congenital diaphragmatic hernia.Local fetal lung renin-angiotensin system as a target to treat congenital diaphragmatic herniaFetal ultrasound markers of severity predict resolution of pulmonary hypertension in congenital diaphragmatic hernia.Risk factors for persistent pulmonary hypertension of the newborn.Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.Fetal Stomach Position Predicts Neonatal Outcomes in Isolated Left-Sided Congenital Diaphragmatic Hernia.Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheepPeroxisome proliferator activated receptor-γ-Rho-kinase interactions contribute to vascular remodeling after chronic intrauterine pulmonary hypertension.Vascular abnormalities in human newborns with pulmonary hypertension.Update in pediatric lung disease 2010.Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.Role of reactive oxygen species in neonatal pulmonary vascular disease.Pharmacodynamic considerations in the treatment of pulmonary hypertension in infants: challenges and future perspectives.Challenges, priorities and novel therapies for hypoxemic respiratory failure and pulmonary hypertension in the neonate.Neuroendocrine factors regulate retinoic acid receptors in normal and hypoplastic lung development.Looking beyond PPHN: the unmet challenge of chronic progressive pulmonary hypertension in the newbornCongenital diaphragmatic hernias: from genes to mechanisms to therapies.[Extracorporeal membrane oxygenation in children].Endothelin-1 decreases endothelial PPARγ signaling and impairs angiogenesis after chronic intrauterine pulmonary hypertension.Diagnosis and treatment of pulmonary hypertension in infancy.Changes in vasoactive pathways in congenital diaphragmatic hernia associated pulmonary hypertension explain unresponsiveness to pharmacotherapy.PBX transcription factors drive pulmonary vascular adaptation to birth.MicroRNA-27a/b mediates endothelin-1-induced PPARγ reduction and proliferation of pulmonary artery smooth muscle cells.Continuous intravenous sildenafil as an early treatment in neonates with congenital diaphragmatic hernia.
P2860
Q27022763-A5784D54-064B-4EF9-A185-6F88D5458A3BQ30251927-C10C21F8-3493-442C-A170-D4D3C92090B4Q33166789-5BD200AB-18B3-42F7-A524-BF1773F2A0CCQ34182389-EFAABF8B-7047-4895-B752-3404007F7F37Q34516884-E35EAB37-8215-4538-A76C-E302DD0E06AFQ35019870-395BDB4F-E663-4D89-ABC7-FC1D22969372Q35084278-25136D37-894E-4D78-BA32-04A31A2DB53BQ35186599-A0983216-F023-4E45-A5C2-4FBFEA86ED80Q35872512-8AA14884-FBED-409D-AF2A-4269E909D9A2Q35901189-48FC5806-D204-4570-BBB2-3C92B1A93ACBQ35929737-07B78C10-9DAB-48CD-9E25-E8E403F2A05EQ36730928-580A9E04-7338-405A-815D-30006FBAD4A5Q36900955-78BAB778-E981-4E7A-BE78-0FAD3602C69FQ37157879-EAE0E4AE-DCA9-49F6-940F-55E7B39FBF11Q37576061-34F0DA5B-E0B1-467F-AA55-A210A428D00FQ37867675-5E494E87-A7CB-427D-A61A-9D8481757272Q37885064-1FED91C4-7422-4040-99CF-58364C623364Q37985076-7046B29E-5C8D-42B8-9975-63CFF87ADAE3Q38172267-B7780E71-12C1-4208-B9A4-3D3C729134CDQ38630552-A4ACA90F-0340-4D6E-BC59-DDE034EB8CF5Q38844488-E1AC7DA8-76E4-47F2-A622-3A35CD37E70EQ40814243-04248D1C-4258-4857-ABBC-DC0DAF1A20B8Q41180077-1FFCB219-85DA-4FEA-9609-EDDA38CFA978Q41440531-C810C38F-780D-4C86-96A9-7E8DE786D7A9Q41488773-D6EECF1F-4CCF-407E-94E2-C56567D170D4Q41943805-D2844847-0FF1-4AB2-ACC9-85CDB2F38A97Q42508912-E7EA4299-7B80-4BB8-88E2-BBF67C3F874CQ47142587-EB1FEF92-F90A-4026-B68B-7FE264C19291Q47240063-C0BFAAC0-0754-435E-BD19-AD2700679834Q47897511-07226329-B493-4AAC-AC34-20D08CC6D08EQ48279014-A9BD1270-45B5-4AEB-9DB6-EE3236EA5415
P2860
Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Congenital diaphragmatic herni ...... tension, and disease severity.
@ast
Congenital diaphragmatic herni ...... tension, and disease severity.
@en
Congenital diaphragmatic herni ...... tension, and disease severity.
@nl
type
label
Congenital diaphragmatic herni ...... tension, and disease severity.
@ast
Congenital diaphragmatic herni ...... tension, and disease severity.
@en
Congenital diaphragmatic herni ...... tension, and disease severity.
@nl
prefLabel
Congenital diaphragmatic herni ...... tension, and disease severity.
@ast
Congenital diaphragmatic herni ...... tension, and disease severity.
@en
Congenital diaphragmatic herni ...... tension, and disease severity.
@nl
P2093
P2860
P1476
Congenital diaphragmatic herni ...... tension, and disease severity.
@en
P2093
Anita J Moon-Grady
Jeffrey R Fineman
John Neuhaus
Karen Hendricks-Munoz
Kerilyn K Nobuhara
Phillip Moore
Roberta L Keller
Sam Hawgood
Theresa A Tacy
P2860
P304
P356
10.1164/RCCM.200907-1126OC
P407
P577
2010-04-22T00:00:00Z